ArticleOpen forum infectious diseases2026
Effectiveness of Individualized Autovaccine Immunotherapy in Women With Recurrent Urinary Tract Infections: A Prospective Cohort Study.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recurrent urinary tract infections (rUTIs) disproportionately affect older women and are frequently driven by nonmodifiable risk factors (nmRFs). This study evaluated the effectiveness, safety, and patient-reported outcomes (PROs) of personalized sublingual immunoprophylaxis in women with rUTIs. Methods: Prospective, single-center, noncomparative observational cohort study. Women with rUTIs received a Uromune® autovaccine prepared from inactivated strains isolated from each patient's urine culture (UC). Recurrence episodes and UC results were recorded at baseline and at 3, 9, and 12 months. PROs (daily activity, QAct; emotional distress, QEm) were assessed in a predefined substudy. Longitudinal mixed-effects and population-averaged models evaluated change over time and explored baseline risk factors as effect modifiers. Results: Of 119 screened women, 100 were enrolled (median [IQR] age: 73 [61-80] years); most presented multiple nmRFs. Median (IQR) rUTI episodes decreased from 4 (3-5) at baseline to 0 (0-2) at 3 months and remained 1 (0-2) and 1 (0-3) at 9 and 12 months (all Conclusions: Individualized sublingual immunoprophylaxis was safe and associated with sustained reductions in rUTI episodes, improved microbiological findings, and better emotional well-being, suggesting a potential role as a nonantibiotic preventive strategy. These observational findings are hypothesis-generating and warrant confirmation in controlled studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.